The Blood and Marrow Transplant Program at Northside Hospital is a collaboration between The Blood and Marrow Transplant Group of Georgia (BMTGA) and Northside Hospital.

For questions, call (404)-255-1930
Survival Data

 

Over Performing 2009 - 2016: Survival Outcome Rates in Allogeneic and Unrelated Donor Transplants

The NSH BMT Program is the only adult BMT Program in Georgia, to achieve survival outcomes that significantly exceeded the expected survival rate for allogeneic and unrelated donor transplants for the last 8 consecutive reporting cycles (2009-2016) 1,2. Over the past eight years, we believe our programs’ commitment to quality has consistently increased patient survival rates. There were 179 adult and pediatric transplant centers included in the analysis.

 

 

 

Dedicated to Clinical Excellence & Remarkable Patient Satisfaction

  • Allogeneic one year survival outcomes that are among the best in the nation.*
  • Physicians available 24 Hours/7 Days a week.
  • Inpatient and outpatient transplant program.
  • Dedicated specialty trained clinical team.
  • Survivorship events.
  • Satisfaction survey results consistently above the 90th percentile for physician care, nursing care and overall hospital experience.**

Innovative Research Programs & Partnerships

  • One of 20 core clinical centers for the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN).
  • Selected participant in The Blood Cancer Research Partnership (BCRP) in collaboration with the Dana Farber Cancer Institute.
  • Partnership with the National Cancer Institute Community Oncology Research Program (NCORP).

Focus on Quality
Successful re-accreditation with the Foundation for the Accreditation of Cellular Therapy (FACT), with no clinical deficiencies noted, for the last 5 consecutive inspections spanning 2003-2015.


For more information please visit https://bethematch.org/tcdirectory/index/60

To view our Survival Information Brochure, click here.

 

1. Reported outcome data from bethematch.org. This survival information includes only patients who received their first allogeneic transplant between January 1, 2012 and December 31, 2014 using unrelated or related donors, and who had reported follow-up.
2. Final 2016 Transplant Center Specific Survival Report, December 12, 2016.